Innovent Biologics Reports H1 Net Profit of RMB 1.253 Billion, Up 50.2% YoY
nashnova research
Innovent Biologics reported H1 net profit of RMB 1.253 billion, up 50.2% year-on-year, as product revenue growth far outpaced total revenue — commercialization is converting into earnings at an accelerating pace.
What do the headline numbers say?
Total revenue hit RMB 8.618 billion, up 44.8% YoY; net profit reached RMB 1.253 billion, up 50.2%.
Profit grew faster than revenue. This means → the company is not just selling more — it is selling more efficiently.
Non-IFRS net profit — stripping out share-based compensation and other non-recurring items — came in at RMB 1.704 billion, up 40.5%, driven by volume ramp and improving operating leverage.
Why did product revenue outrun total revenue?
H1 product revenue was RMB 8.202 billion, up 56.7% — well above the 44.8% growth in total revenue.
In plain terms = total revenue includes licensing fees and other non-product items; the drugs themselves are selling even faster, showing the company's own commercial engine is accelerating.
This reflects a portfolio that has moved past the channel-building phase and into full-scale volume harvesting.
Twenty approved products — how broad is the base?
Innovent now has 20 approved products spanning oncology, autoimmune diseases, and metabolic disorders.
13 of those are listed on the National Reimbursement Drug List (NRDL) — a 65% inclusion rate.
This means → more than six in ten products carry state insurance coverage, lowering the barrier to volume uptake; newly reimbursed oncology drugs ramping up were a core driver of this period's results.
"The best window since founding" — what is the company betting on?
Management called the current moment "the best development window since the company was founded" and laid out a third strategic transformation.
The target: evolve over the next five to ten years from a leading domestic biopharma into a globally capable, world-class biologics company.
Multiple international partnerships landed in H1, but whether that globalization push converts into quantifiable revenue in H2 will be the market's key watch point.
市场有风险，内容仅供研究参考，不构成投资建议。